Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
KDM4A is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein containing a JmjN domain, a JmjC domain, a JD2H domain, two TUDOR domains, and two PHD-type zinc fingers. Additionally we are shipping KDM4A Proteins (5) and KDM4A Kits (4) and many more products for this protein.
Showing 10 out of 118 products:
Human Polyclonal KDM4A Primary Antibody for EIA, WB - ABIN356585
Whetstine, Nottke, Lan, Huarte, Smolikov, Chen, Spooner, Li, Zhang, Colaiacovo, Shi: Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. in Cell 2006
Show all 3 references for ABIN356585
Human Monoclonal KDM4A Primary Antibody for ICC, IHC - ABIN969230
Suzuki, Yamashita, Shirota, Sakakibara, Chiba, Mizushima-Sugano, Nakai, Sugano: Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions. in Genome research 2004
Show all 3 references for ABIN969230
Human Monoclonal KDM4A Primary Antibody for EIA, IF - ABIN1107893
Tao, Wollscheid, OBrien, Eng, Li, Bodenmiller, Watts, Hood, Aebersold: Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry. in Nature methods 2005
Show all 2 references for ABIN1107893
Human Polyclonal KDM4A Primary Antibody for EIA, IHC (p) - ABIN500080
Gray, Iglesias, Lizcano, Villanueva, Camelo, Jingu, Teh, Koibuchi, Chin, Kokkotou, Dangond: Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. in The Journal of biological chemistry 2005
KDM4A downregulation promotes autophagy in glioma cell lines.
ERG (show ERG Antibodies) promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1 (show YAP1 Antibodies). A corollary is that KDM4A as well as YAP1 (show YAP1 Antibodies) inhibitors may prove beneficial for the therapy of ERG (show ERG Antibodies)-overexpressing prostate tumors.
In pancreatic neoplasms, miR (show MLXIP Antibodies)-137 targets KDM4A mRNA during Ras-induced senescence and activates both p53 (show TP53 Antibodies) and retinoblastoma (pRb (show RB1 Antibodies)) tumor suppressor pathways.
Study demonstrates that JMJD2A contributes to tumorigenesis in non-small cell lung cancer (NSCLC) by regulating miR (show MLXIP Antibodies)-150. Additionally, JMJD2A overexpression is associated with a poor prognosis for NSCLC patients.
High KDM4A expression is associated with endometrial cancer progression.
Studies indicate that histone lysine demethylase (show MBD2 Antibodies) (JmjC-KDM) KDM4A protein has been implicated in numerous cancers and cardiovascular diseases.
KDM4A is regulated by hsa (show CD24 Antibodies)-mir (show MLXIP Antibodies)-23a-3p, hsa (show CD24 Antibodies)-mir (show MLXIP Antibodies)-23b-3p, and hsa (show CD24 Antibodies)-mir (show MLXIP Antibodies)-137.
these data reveal a JMJD2A/ETV1 (show ETV1 Antibodies)/YAP1 (show YAP1 Antibodies) axis that promotes prostate cancer initiation and that may be a suitable target for therapeutic inhibition.
Results indicate that SCF (show KITLG Antibodies)(Fbxo22 (show FBXO22 Antibodies))-KDM4A is an E3 ubiquitin ligase (show MUL1 Antibodies) that targets methylated p53 (show TP53 Antibodies) and regulates key senescent processes.
This study showed that KDM4A interacts with RNA Polymerase I (show POLR1C Antibodies), associates with active ribosomal RNA genes and is required for serum-induced activation of rDNA transcription.
These findings together demonstrate the essential role of KDM4A and KDM4C (show KDM4C Antibodies) in orchestrating mESC differentiation to endothelial cells through the activation of Flk1 (show KDR Antibodies) and VE-cadherin (show CDH5 Antibodies) promoters, respectively
As well as three novel motifs in JMJD2A-regulated genes.
JMJD2A bound to the FHL1 (show FHL1 Antibodies) promoter in response to TAC (show IL2RA Antibodies), upregulated FHL1 (show FHL1 Antibodies) expression, and downregulated H3K9 trimethylation. JMJD2A promotes cardiac hypertrophy under pathological conditions by a novel mechanism.
JHDM3A(GFP)(701) is a suitable catalytic module that can be targeted, under the control of a guide protein, to specific loci where the chromatin H3K9me3 status and the milieu of gene expression are to be modified.
Histone demethylases KDM3A (show KDM3A Antibodies), KDM4A, and KDM4C (show KDM4C Antibodies) were expressed before and after embryonic genome activation, whereas KDM5B (show KDM5B Antibodies) was mainly expressed during the blastocyst period.
This gene is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein containing a JmjN domain, a JmjC domain, a JD2H domain, two TUDOR domains, and two PHD-type zinc fingers. This nuclear protein functions as a trimethylation-specific demethylase, converting specific trimethylated histone residues to the dimethylated form, and as a transcriptional repressor.
jumonji domain containing 2A
, lysine (K)-specific demethylase 4A
, lysine-specific demethylase 4A
, jumonji domain-containing protein 2A
, JmjC domain-containing histone demethylation protein 3A
, jumonji domain-containing 2A
, lysine-specific demethylase 4A-like
, jmjC domain-containing histone demethylation protein 3A
, jumonji C domain-containing histone demethylase 3A
, jumonji domain containing 2
, tudor domain containing 14A